Related Experiment Videos
[Febrile neutropenia: practical aspects]
P Harten1, B Seyfarth, N Schmitz
1II. Medizinische Klinik und Poliklinik, Christian-Albrechts-Universität Kiel. P.Harten@2med.uni-kiel
Medizinische Klinik (Munich, Germany : 1983)
|December 16, 1998
Summary
Managing febrile neutropenia requires strategic antibiotic use to achieve high response rates. Further research is needed to explore outpatient treatment options for select patients.
Area of Science:
- Infectious Diseases
- Hematology
- Pharmacoeconomics
Context:
- Febrile neutropenia poses a significant mortality risk in patients undergoing chemotherapy or with other conditions causing low neutrophil counts.
- Effective management is crucial to reduce prolonged hospital stays and high healthcare costs associated with infections in this vulnerable population.
Purpose:
- To review the practical and economic considerations for managing febrile neutropenia.
- To outline current therapeutic strategies and their efficacies.
Summary:
- First-line treatments include aminoglycosides with ureidopenicillin or third-generation cephalosporins; double beta-lactam combinations offer similar efficacy with reduced toxicity but higher cost.
- Monotherapy with carbapenems, ceftazidime, or cefepime shows comparable effectiveness.
- For persistent infections or lung infiltrates, escalating therapy with carbapenems, glycopeptides, and antifungals is recommended. Hematopoietic growth factors are reserved for high-risk cases.
Impact:
- The discussed therapeutic approach achieves response rates exceeding 90%.
- Consistent, stepwise antibiotic escalation is key to successful outcomes.
- Further investigation is warranted to determine the feasibility and safety of outpatient management for selected patients with febrile neutropenia.